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The Case for Myocardial Ischemia
in Hypertrophic Cardiomyopathy
Martin S. Maron, MD,* Iacopo Olivotto, MD,† Barry J. Maron, MD,‡ Sanjay K. Prasad, MD,§
Franco Cecchi, MD,† James E. Udelson, MD,* Paolo G. Camici, MD
Boston, Massachusetts; Florence, Italy; Minneapolis, Minnesota; and London, United Kingdom
Since its original description 50 years ago, myocardial ischemia has been a recognized but underappreciated
aspect of the pathophysiology of hypertrophic cardiomyopathy (HCM). Nevertheless, the assessment of myocar-
dial ischemia is still not part of routine clinical diagnostic or management strategies. Morphologic abnormalities
of the intramural coronary arterioles represent the primary morphologic substrate for microvascular dysfunction
and its functional consequence—that is, blunted myocardial blood flow (MBF) during stress. Recently, a number
of studies using contemporary cardiovascular imaging modalities such as positron emission tomography (PET)
and cardiovascular magnetic resonance (CMR) have led to an enhanced understanding of the role that myocar-
dial ischemia and its sequelae fibrosis play on clinical outcome. In this regard, studies with PET have shown that
HCM patients have impaired MBF after dipyridamole infusion and that this blunted MBF is a powerful indepen-
dent predictor of cardiovascular mortality and adverse LV remodeling associated with LV systolic dysfunction.
Stress CMR with late gadolinium enhancement (LGE) has also shown that MBF is reduced in relation to magni-
tude of wall thickness and in those LV segments occupied by LGE (i.e., fibrosis). These CMR observations show
an association between ischemia, myocardial fibrosis, and LV remodeling, providing support that abnormal MBF
caused by microvascular dysfunction is responsible for myocardial ischemia-mediated myocyte death, and ulti-
mately replacement fibrosis. Efforts should now focus on detecting myocardial ischemia before adverse LV re-
modeling begins, so that interventional treatment strategies can be initiated earlier in the clinical course to miti-
gate ischemia and beneficially alter the natural history of HCM. (J Am Coll Cardiol 2009;54:866–75) © 2009
by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.072p
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sypertrophic cardiomyopathy (HCM) is the most common
enetic heart disease, with a prevalence in the general
opulation of 1:500, and characterized by extreme hetero-
eneity with regard to phenotypic expression, pathophysi-
logy, and clinical course (1–5). HCM is the most common
ause of sudden cardiac death in the young, but also a major
ause of heart failure disability at any age (6–9). Myocardial
schemia is an established pathophysiologic feature in HCM
nd may be associated with important disease-related com-
lications that impact clinical outcome, including adverse
eft ventricular (LV) remodeling and systolic dysfunction
10–20). Nevertheless, for much of the past 50 years,
schemia has been an underappreciated (or unrecognized)
omponent of the HCM disease process, particularly com-
rom the *Hypertrophic Cardiomyopathy Center, Division of Cardiology, Tufts
edical Center, Boston, Massachusetts; †Regional Referral Center for Myocardial
iseases, Azienda Ospedaliera Universitaria Careggi, Florence, Italy; ‡Hypertrophic
ardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis,
innesota; §Center for Advanced MR in Cardiology and Department of Cardiology,
oyal Brompton Hospital, London, United Kingdom; and the Medical Research
ouncil Clinical Sciences Centre and National Heart and Lung Institute, Imperial
ollege, London, United Kingdom.a
Manuscript received February 25, 2009; revised manuscript received April 20,
009, accepted April 21, 2009.ared with the better-known pathophysiologic mechanisms
f LV outflow obstruction (21–23) and diastolic dysfunction
24–26).
Although perfusion defects on thallium-201 single-
hoton emission computed tomography (SPECT) were
onvincingly shown in HCM patients more than 25 years
go (27,28), assessment of myocardial ischemia is currently
ot part of routine clinical diagnostic or management
trategies in this disease (4). This limitation almost certainly
mpacts our capability for providing a more comprehensive
valuation of individual HCM patients.
More recently, a number of studies using contemporary
ardiovascular imaging modalities such as positron emission
omography (PET) and cardiovascular magnetic resonance
CMR) imaging have led to an enhanced understanding
f the role that myocardial ischemia plays in this complex
nd heterogeneous genetic disease (12,29 –34). There-
ore, we believe it is particularly timely to focus attention
n the current understanding of myocardial ischemia in
CM and its importance as a potential prognostic marker
nd to revisit the contribution of contemporary imaging
trategies for assessment, as well as possible treatment
pproaches.
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August 25, 2009:866–75 Imaging and Ischemia in HCMathophysiology, Substrate, and Biomarker Evidence
or Myocardial Ischemia
athologic and hemodynamic evidence. The initial evi-
ence for myocardial ischemia in HCM was derived from
ost-mortem studies of patients who had died suddenly and in
hom extensive areas of myocardial damage were evident. A
pectrum of ischemic injury was observed, from an acute phase
ith coagulative necrosis and neutrophilic infiltrate to a
hronic post-necrotic replacement-type fibrosis, always in the
bsence of atherosclerotic epicardial coronary artery disease
35).
In addition to gross pathologic evidence of myocardial
carring, autopsy studies in HCM patients have shown struc-
ural abnormalities of intramural coronary arterioles, character-
zed by thickening of the intima and/or medial layers of the
essel wall associated with decreased luminal cross-sectional
rea (Fig. 1) (35–40). Indeed, these morphologic abnormalities
f the intramural coronary arterioles (i.e., small vessel disease)
ost likely represent the primary morphologic substrate for
icrovascular dysfunction (i.e., impaired vasodilatory capacity)
nd its functional consequence, that is, blunted myocardial
lood flow (MBF) during stress (i.e., hypoperfusion) (41–43).
Periods of abnormal MBF occur in patients with HCM
ecause of the increased myocardial oxygen demand of the
ypertrophied ventricular myocardium, and in patients with
V outflow tract obstruction metabolic demand is further
ncreased because of the greater workload induced by
ubstantially elevated intraventricular pressures. Although
ot all episodes of abnormal MBF lead to ischemia, such
ircumstances arise frequently enough during the clinical
ourse of an HCM patient that absolute MBF can be
egarded as a surrogate for myocardial ischemia. Other
tructural abnormalities, including myocyte disarray, in-
A
Figure 1 Small-Vessel Disease and the Morphologic Basis for M
(A) Native heart of a patient with end-stage HCM who underwent transplantation.
(white arrows). (B) Intramural coronary artery in cross-section showing thickene
(C) Area of myocardium with numerous abnormal intramural coronary arteries w
nification 55. Reprinted, with permission, from Maron et al. (38). HCM  hypreased interstitial (matrix) fibro-
is, and reduced capillary density,
ay also contribute to impair-
ent of MBF in HCM (44–48).
iomarker evidence. During
he mid-1980s, elegant invasive
ardiac catheterization studies
rovided the most compelling
nd direct evidence for the pres-
nce of myocardial ischemia in
CM (11,49–51). In the ab-
ence of epicardial coronary ar-
ery disease, patients showed de-
reased lactate consumption
sampled from the great cardiac
ein via the coronary sinus) dur-
ng rapid atrial pacing in associ-
tion with decreased venous flow
nd elevated LV end-diastolic
ressures (52).
Because the great cardiac vein is responsible for venous
rainage from the vascular territory supplying the anterior
eptum (the most common location for LV hypertrophy in
CM), these findings were regarded as evidence of myo-
ardial ischemia (11). Furthermore, elevations in serum
iomarkers of cardiac injury (i.e., troponin) have also been
ocumented in this disease (53). Because increases in
roponin show high specificity for myocyte cell death, this
bservation provides further evidence for a process of
ubclinical myocardial ischemia.
Therefore, it was more than 25 years after the contem-
orary description of HCM in 1958 that evidence from
ost-mortem and invasive hemodynamic studies convinc-
rdial Ischemia in HCM
areas of gross macroscopic scarring are evident throughout the LV myocardium
al and medial layers of the vessel wall associated with small luminal area.
a region of scarring, adjacent to an area of normal myocardium. Original mag-
hic cardiomyopathy; LV  left ventricular.
Abbreviations
and Acronyms
CMR  cardiovascular
magnetic resonance
HCM  hypertrophic
cardiomyopathy
ICD  implantable
cardioverter-defibrillator
LGE  late gadolinium
enhancement
LV  left ventricular
MBF  myocardial blood
flow
PET  positron emission
tomography
SPECT  single-photon
emission computed
tomographyB
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Imaging and Ischemia in HCM August 25, 2009:866–75ngly showed that myocardial ischemia occurs in this dis-
ase. Indeed, the consequences of repetitive bouts of isch-
mia include myocyte death and associated myocardial
eplacement fibrosis leading to adverse LV remodeling in
he form of regional replacement fibrosis and loss of
yocyte function. This will result in altered diastolic func-
ion, and in some patients, progression to systolic dysfunc-
ion (i.e., the end-stage phase of HCM) (Fig. 2).
oninvasive Assessment of
icrovascular Function and Myocardial Ischemia
urrently, no technique allows the direct visualization of
he coronary microcirculation in vivo in humans. Therefore,
he assessment of myocardial ischemia relies on the mea-
urement of parameters such as MBF that reflect microvas-
ular dysfunction. Over the past 3 decades, several nonin-
asive tests have assessed coronary microvascular function
nd myocardial ischemia in patients with HCM (Table 1).
ET. The most reliable noninvasive method for assessing
yocardial ischemia in HCM by quantitative measurement
f its surrogate MBF (29,54) is PET with either 13N-
abeled ammonia or 15O-labeled water. The measurement
f MBF under basal conditions and in conditions of
ear-maximal vasodilatation (after intravenous adenosine or
ipyridamole) permits calculation of coronary flow reserve,
hat is, the ratio of maximum to basal MBF. In the absence
f obstructive epicardial coronary disease, flow resistance is
rimarily determined by the microvasculature (90% of cor-
nary resistance resides in arterioles 300 m in diameter),
Figure 2 Proposed Cascade of Pathophysiologic Events Leadin
Abnormal microvascular remodeling promotes blunted myocardial blood flow leadin
myocardial ischemia, fibrosis, and adverse LV remodeling in HCM. Abbreviations and therefore a reduced coronary flow reserve (and MBF) are
arkers of coronary microvascular dysfunction (17).
In patients with HCM, PET studies have shown that
lthough resting MBF is similar to that of normal control
ubjects, the increase of blood flow after dipyridamole
nfusion is significantly blunted, reflecting an inability to
ncrease myocardial perfusion to match increased demand
10,30,55,56). For example, maximum MBF after dipyri-
amole stress in HCM patients is often 2 ml/min/g,
ompared with an average of 4 ml/min/g in healthy control
ubjects. Furthermore, flow abnormalities are most pro-
ound in the subendocardium, including reduced flow in
reas of myocardium contiguous to segments in which
erfusion is preserved (10). Therefore, although MBF is
ften markedly impaired in the hypertrophied ventricular
eptum, it may also be reduced in the nonhypertrophied
ortions of the LV wall (10). These observations suggest a
rimary and diffuse impairment of coronary microvascular
unction in HCM, a finding that is supported by post-
ortem studies showing evidence of abnormal intramural
oronary arterioles distributed throughout the LV myocar-
ium (35,38,40). In addition, abnormalities of MBF during
ipyridamole stress are more pronounced in the subendo-
ardial layer compared with the subepicardium (Figs. 3A
nd 3B), consistent with the SPECT finding of transient
schemic dilatation (10,17,30).
MR. CMR provides 3-dimensional tomographic imag-
ng of the heart with high spatial and temporal resolution, in
ny plane and without ionizing radiation (33,57,58). After
yocardial Ischemia in HCM
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August 25, 2009:866–75 Imaging and Ischemia in HCMhe first pass of intravenous gadolinium administration,
MR perfusion sequences permit both qualitative and
uantitative assessment of MBF at rest and during pharma-
ologic stress (typically adenosine) with superior spatial
esolution compared with PET or SPECT (33,34,58).
urthermore, after a delay of approximately 10 to 15 min
Figure 3 Evidence of Myocardial Ischemia and Fibrosis by PET
(A and B) A 23-year-old patient with HCM and massive asymmetric ventricular septa
uptake by PET can be seen at the base of the anterior papillary muscle (11 o’cloc
increases more substantially in the subepicardial than in the subendocardial ventr
Relationship of abnormal myocardial blood flow by PET and areas of myocardial fib
patient with HCM, with color scale showing highest myocardial blood flow in red an
corresponding short-axis contrast-enhanced CMR image showing areas of late gad
myocardial blood flow by PET. Reprinted, with permission, from Sotgia et al. (65).
other abbreviations as in Figure 1.
linical Relevance and Limitations of Different Techniques forhe Assessment of Microvascular Dysfunctio and Ischemia in HCMTable 1 Cli ical Rele n e nd Lim ta s of Different Techniqthe Assessment of Microvascular Dysfunction and Isch
Method Finding
Clinical history Nonanginal chest pain Ong
Troponin I Increased serum levels Acu
Holter ECG ST-T changes Ong
Exercise testing ST-T changes/symptoms Indu
Stress echocardiography Regional wall motion abnormalities Indu
SPECT Regional perfusion abnormalities Reg
p
Coronary angiography Myocardial bridging/tunneling of
LAD, associated CAD
Exc
Coronary lactate (serum) levels Lactate production Ana
PET Reduced coronary reserve/blunted
maximal MBF
Exte
d
r
CMR–stress perfusion Reduced coronary reserve/blunted
maximal MBF
Exte
d
CMR–late gadolinium
enhancement
Delayed contrast enhancement Rep
i
AD  coronary artery disease; CMR  cardiovascular magnetic resonance; ECG  electrocardio
entricular; MBF  myocardial blood flow; PET  positron emission tomography; SPECT  single-fter the acquisition of the first-pass perfusion images, late
adolinium enhancement (LGE-CMR) sequences can
dentify the presence (and quantitatively measure the extent)
f myocardial fibrosis in HCM patients (32,59–61). Evi-
ence that areas of LGE represent myocardial fibrosis in
CM can be found in a small number of case reports of
MR
trophy (wall thickness 39 mm). At baseline (A), an area of reduced 13N-ammonia
tion; arrow). (B) PET after dipyridamole stress, in which myocardial blood flow
septum (VS) as well as the contiguous anterior LV wall (Ant. FW). (C and D)
y contrast-enhanced CMR. (C) A PET short-axis slice at the basal LV level in a
est in green. (D) In the same patient, after intravenous infusion of gadolinium, a
enhancement (bright) that match closely to the identical areas of abnormal
cardiovascular magnetic resonance; PET  positron emission tomography;
or
in HCM
Clinical Relevance Limitations
icrovascular ischemia Poor sensitivity and specificity. Should
prompt investigation for alternative
causes if severe (CAD, bridging).
cyte injury Limited utility in HCM due to frequent lack
of symptoms during ischemia. If
markedly elevated in association with
symptoms, should also prompt
exclusion of CAD.
chemia Poor sensitivity; baseline ECG
abnormalities often limit reliability.
ischemia Poor sensitivity; baseline ECG
abnormalities often limit reliability.
ischemia Limited experience in HCM; likely poorly
sensitive.
icrovascular dysfunction, may
end-stage progression
Lack of MBF quantitation; suboptimal
sensitivity.
of associated causes of ischemia Not practical for assessment of
microvascular function.
metabolism/ischemia Invasive, not applicable in routine clinical
practice.
distribution of microvascular
tion, predicts outcome and LV
ling
Limited availability and expensive.
Radiation exposure.
distribution of microvascular
tion
Still not widely available; time consuming/
expensive. Validation less robust
than PET.
ent scarring after recurrent
ia
Prognostic significance still under
investigation.
HCM  hypertrophic cardiomyopathy; LAD  left anterior descending coronary artery; LV  left
emission computed tomography.and C
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Imaging and Ischemia in HCM August 25, 2009:866–75nd-stage patients in which concordance has been shown
etween in vivo LGE-CMR images and gross and his-
opathological findings of fibrosis in native hearts after
ransplantation (62,63). Therefore, CMR affords an oppor-
unity to provide insights into the pathophysiology of
yocardial ischemia in HCM by matching areas of abnor-
al perfusion with other important morphologic findings
uch as segmental LV hypertrophy and fibrosis.
Similar to PET, a recent stress CMR study in HCM
howed blunted MBF in response to stress. In addition,
BF was reduced to a greater degree in the subendocardial
ompared with the subepicardial layer, and also the degree
f abnormal perfusion related to magnitude of wall thick-
ess (34). Importantly, areas of myocardium in which
brosis was present (as determined by LGE) were most
ften associated with reduced MBF (34). Furthermore,
yperemic flow was substantially reduced in LV segments
ccupied by LGE as well as severely blunted in areas
ituated adjacent to myocardial fibrosis (Figs. 3C and 3D)
64,65). Taken together, these CMR observations show an
ssociation between ischemia, myocardial fibrosis, and LV
emodeling, providing further support for the principle that
bnormal MBF caused by microvascular dysfunction is
esponsible for myocardial ischemia–mediated myocyte
eath, and ultimately repair in the form of replacement
brosis.
Finally, abnormalities of MBF assessed with PET and
etection of myocardial fibrosis with contrast-enhanced
MR have also been shown previously in patients with LV
ypertrophy caused by longstanding pressure overload from
ystemic hypertension or aortic stenosis, as well as other
ardiomyopathies (e.g., Anderson-Fabry disease) (29).
ased on these studies, we conclude that diffuse impairment
n the coronary microvasculature leading to ischemia and
ltimately myocardial scarring is not a process unique to
CM and occurs in a similar fashion in other forms of
rimary and secondary LV hypertrophy.
adionuclide myocardial perfusion imaging. Using the
otassium analogue thallium-201 or the 99mTc labeled
ompounds as perfusion tracers (11,16,27,28,66,67),
PECT myocardial perfusion imaging has shown both fixed
nd reversible myocardial perfusion defects in HCM pa-
ients. Fixed defects are more often associated with reduced
ystolic function, lower peak oxygen consumption, and
ncreased LV cavity dimensions, and consequently have
een regarded as areas of myocardial scarring (16). Revers-
ble defects induced by exercise have been considered
arkers of myocardial ischemia based on high concordance
ith metabolic evidence of ischemia induced by pacing or
nfusion of sympathomimetic drugs (11). That reversible
efects reflect a dynamic abnormality of coronary microvas-
ular function is also suggested by the reduction of such
efects reported with verapamil therapy (66). In HCM,
PECT imaging has also shown stress-induced transient
avity dilatation, suggestive of diffuse subendocardial isch-
mia. Although SPECT imaging is widely available, this sechnique is limited by allowing only the assessment of
elative changes in regional perfusion and by an inability to
uantify absolute MBF.
lectrocardiographic monitoring. Traditional, noninva-
ive methods for detecting myocardial ischemia clinically,
ncluding ST-segment changes on 12-lead and ambulatory
olter electrocardiographic monitoring or exercise testing,
ave proved to be insufficiently sensitive or specific for
etecting ischemia in HCM (17). ST-segment depression
uring Holter monitoring occurs commonly in HCM pa-
ients both during exertion and while sedentary, but has not
een consistently linked with either chest pain or perfusion
bnormalities on SPECT imaging (68).
linical Evidence for Ischemia
hest pain symptoms are a frequent complaint among 25%
o 50% of HCM patients (3,4,68). Episodes of chest pain in
atients with HCM can be prolonged and atypical in
haracter, occurring frequently under resting conditions
69), but also may be consistent with classic angina pectoris
rovoked with exertion and after meals (68). However, the
elationship among the various types of chest pain en-
ountered in HCM and active myocardial ischemia is at
resent unresolved. In those HCM patients with typical
ngina in whom suspicion of underlying epicardial coro-
ary artery disease is increased based on more advanced
ge, assessment of traditional coronary risk factors and
ertinent noninvasive testing, coronary angiography (or
lternatively cardiac computed tomographic angiography)
hould be considered to exclude obstructive atheroscle-
otic coronary artery disease (70) as well as other causes of
hest pain (e.g., myocardial bridging or congenital coro-
ary artery anomalies).
Electrocardiographic changes consistent with ischemia
uch as ST-segment depression may occur frequently during
xercise testing and Holter monitoring, but are most often
ot associated with chest pain (27,68). Consequently, a clear
ssociation between chest pain and microvascular ischemia
as not been established in HCM, suggesting that ischemia
ften occurs silently (11). In one study of young asymptom-
tic HCM patients, reversible thallium perfusion defects
ere present in about 50% of patients, supporting the
oncept of clinically silent ischemia (66). In addition, no
onsistent relationship has been established between chest
ain and LV wall thickness, outflow obstruction, or other
CM disease features (3).
Verapamil and beta-blockers may improve symptoms of
hest pain and exertional dyspnea in HCM. This probably
ccurs via reduction in heart rate and oxygen consumption
beta-blockers), and possibly because of direct effects on the
icrovasculature and diastolic filling (verapamil), leading to
edistribution of transmural MBF and improved subendo-
ardial perfusion (56). In this regard, verapamil has been
hown to decrease or eliminate reversible myocardial perfu-
ion abnormalities on SPECT imaging, and therefore is
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August 25, 2009:866–75 Imaging and Ischemia in HCMenerally the preferred initial therapy for treating predom-
nant chest pain symptoms in HCM patients (4). Also, in
ecognition of the known clinical benefit of septal reduc-
ion therapies in reducing subendocardial ischemia, con-
ideration should be given to these procedures to relieve
utflow obstruction in HCM patients with advanced
ymptoms of severe debilitating chest pain refractory to
rug therapy (49). In this regard, there is now evidence
howing an improvement in myocardial perfusion after
eptal reduction therapy (71).
linical Significance of Myocardial Ischemia
bservations with PET. Although a number of observations
ad been made defining the presence of myocardial ischemia in
CM over the last 25 years (16,19,20,27,49,52,67), it was the
tudy by Cecchi et al. in 2003 (12) that provided the initial
vidence that ischemia does in fact have important prog-
ostic disease consequences. In a cohort of 51 HCM
Figure 4 Blunted Myocardial Blood Flow With Stress Is Associa
(A) Comparison of LV end-diastolic dimension and ejection fraction at the time of
dipyridamole infusion. Those patients with a dipyridamole myocardial blood flow va
tion. Vertical bars indicate mean  SD for each group. *p  0.05 versus same g
0.05 versus patients in other tertiles. Reprinted, with permission, from Olivotto et
come in patients with HCM. Cardiovascular mortality was highest in those HCM pa
dial blood flow. Reprinted, with permission, from Cecchi et al. (12). PET  positroatients followed prospectively for more than 8 years after
dentification of ischemia by PET, a dipyridamole MBF in
he lowest tertile proved to be a powerful independent
redictor of cardiovascular mortality (Fig. 4) (12). Specifically,
ncreased risk was associated with MBF 1.1 ml/g/min with
relative risk of 9.6 for cardiovascular death and 20.0 for
nfavorable outcome. Although at the time of the initial PET
tudies none of the patients had severe limiting symptoms
nd few were regarded as high-risk for disease progression,
mpaired MBF after dipyridamole nevertheless predicted
ubsequent major cardiovascular events.
Furthermore, patients with the greatest impairment of
BF were more likely to experience long-term LV remod-
ling with end-diastolic LV chamber enlargement and wall
hinning, and decline in systolic function (i.e., to the
nd-stage) (Fig. 4) (72). Specifically, all patients in this
ohort who subsequently progressed to the end stage, and in
hom severe heart failure symptoms developed were in the
With Adverse LV Remodeling and Predicts Outcome
udy and at final evaluation expressed as tertiles of myocardial blood flow after
the lowest tertile showed the greatest change in cavity size and ejection frac-
t the time of PET scan; †p  0.05 versus patients in the highest tertile; ‡p 
). (B) Evidence that myocardial blood flow by PET predicts adverse disease out-
with a dipyridamole myocardial blood flow value in the lowest tertile of myocar-
sion tomography; other abbreviations as in Figure 1.ted
PET st
lue in
roup a
al. (72
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n emis
l
T
v
i
fi
p
l
b
b
b
O
e
a
A
r
c
t
i
r
m
s
t
t
s
m
t
i
t
c
r
d
t
H
r
s
L
s
i
a
s
t
r
p
m
c
a
O
p
L
p
o
e
(
i
m
p
o
u
p
g
a
u
a
f
p
o
n
t
872 Maron et al. JACC Vol. 54, No. 9, 2009
Imaging and Ischemia in HCM August 25, 2009:866–75owest tertile of dipyridamole MBF flow at study entry.
herefore, severe abnormalities in MBF caused by micro-
ascular dysfunction seemed to be a powerful determinant of
mpaired systolic function, whereas preserved MBF identi-
ed the low-risk subgroup (72). Finally, the proportion of
atients who received potential anti-ischemic pharmaco-
ogic agents (such as beta-blockers or calcium-channel
lockers) was statistically similar within each tertile of MBF
oth at the time of PET and during follow-up.
This study was not designed to determine the primary
enefit of these anti-ischemic agents on clinical outcome.
n the other hand, in another study, verapamil reversed or
liminated stress-induced perfusion abnormalities (presum-
bly from small vessel disease) on SPECT imaging (66).
lthough this study did not address whether the benefit in
educing perfusion defects with verapamil improved out-
ome. Nevertheless, it would be reasonable to consider such
herapy in HCM patients with evidence of myocardial
schemia. Given the paucity of data presently available with
egard to the benefit of medical intervention on improving
icrovascular function, it would seem premature to offer a
trong recommendation for repeat imaging to assess poten-
ial changes in the presence or magnitude of ischemia after
reatment.
Consequently, the assessment of myocardial ischemia in
elect patients with HCM (with preserved LV function)
ay represent a prognostic tool for identifying those pa-
ients at risk for profound disease progression. This has
mportant clinical implications because HCM patients in
he end stage experience a high rate of unfavorable disease
onsequences, including progressive heart failure (often
equiring heart transplantation) and sudden unexpected
eath (prompting consideration for prophylactic defibrilla-
or implantation). Therefore, it would seem prudent for
CM patients with severely blunted MBF to undergo
egular clinical surveillance (with echocardiography) for pro-
pective detection of changes in heart failure symptoms and
V remodeling (Fig. 5). However, currently, we cannot
trongly advocate for all HCM patients to undergo routine
maging for ischemia given that relevant data are confined to
single-center study (12). Therefore, until additional pro-
pective studies assessing ischemia in HCM are undertaken,
he decision concerning which patients should undergo
outine imaging remains unresolved. Nevertheless, at the
resent time, consideration could be given to assessing
yocardial ischemia in select HCM patients, in whom
oncern persists regarding prognosis after conventional risk
ssessment.
bservations with CMR. Several recent studies in HCM
rovide potential insights into the clinical implications of
GE and ischemic myocardial damage (15,59–61,73). The
resence of LGE has been associated with the development
f heart failure symptoms and an inverse relationship is
vident between the extent of LGE and ejection fraction
59–61); patients who showed the most marked reduction
n ejection fraction 50% (i.e., end-stage phase) had the oost extensive LGE compared with HCM patients with
reserved systolic function (61). Furthermore, the presence
f LGE (but not extent) has been associated with ventric-
lar tachyarrhythmias (including rapid ventricular tachycardia)
resent on ambulatory 24-h Holter electrocardiogram, sug-
esting that contrast-enhanced CMR may define the unstable
rrhythmogenic substrate in HCM, and that LGE could
ltimately serve as a risk marker for sudden death (73).
However, at present, sufficient follow-up data are not
vailable to clarify whether LGE is an independent risk
actor for sudden death in HCM. Therefore, it is probably
remature to make any firm assumptions regarding the role
f LGE in risk stratification for sudden death. We would
ot advocate implantable cardioverter-defibrillator (ICD)
herapy solely on the presence of LGE (i.e., in the absence
Figure 5
Flow Diagram Summarizing Hypothetical
Algorithm That Can Be Considered in the Assessment
and Management of Myocardial Ischemia in HCM
*Consideration could be given to assessing myocardial ischemia in select HCM
patients if concern persists with regard to prognosis after conventional risk
assessment. **If suspicion is sufficiently high for epicardial coronary artery
disease, coronary angiography (or alternatively computed tomographic angiogra-
phy) may be indicated to exclude obstructive coronary artery disease or other
anatomic causes of chest pain (e.g., myocardial bridging or congenital coronary
artery anomalies). †Although there are presently insufficient clinical data to
support a firm recommendation for angiotensin-converting enzyme inhibitors or
aldosterone inhibitors in patients with HCM, these drugs may be considered
based on studies in HCM transgenic mouse models of HCM. ‡The assessment
of active ischemia using stress CMR is an evolving area, and at present there
are no data with this technique relating ischemia to clinical outcome. ACE 
angiotensin-converting enzyme; CMR  cardiovascular magnetic resonance;
ICD  implantable cardioverter-defibrillator; LGE  late gadolinium enhance-
ment; LV  left ventricle; MBF  myocardial blood flow; PET  positron emis-
sion tomography; SCD  sudden cardiac death; SPECT  single-photon
emission computed tomography; other abbreviations as in Figure 1.f any conventional high-risk features). Nevertheless, al-
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August 25, 2009:866–75 Imaging and Ischemia in HCMhough definitive data are not yet available, it is likely that
ome weight can be given to extensive areas of LGE as an
rbitrator in reaching recommendations for prophylactic
CDs in selected patients, particularly when ambiguity
emains concerning individual patient sudden death risk
fter an assessment of the conventional risk markers (73,74).
herefore, the use of contrast-enhanced CMR to detect
GE may be relevant to clinical decision making and
onsiderations for prophylactic ICD therapy in individual
atients (Fig. 5).
uture Research Considerations
dentification (by imaging) and potential therapeutic strat-
gies for microvascular ischemia in HCM are at an early
tage and requires additional investigative effort, given that
ost of our understanding regarding the clinical signifi-
ance of myocardial ischemia in HCM is derived from a
imited number of single-center studies. Consequently,
here is a need for future research considerations to be
irected toward forming larger prospective and well-
esigned multicenter studies to determine: 1) when active
yocardial ischemia begins with respect to the development
f the HCM phenotype, that is, does ischemia precede the
evelopment of LV hypertrophy and, therefore, could be
onsidered an early therapeutic target; 2) the pathophysiologic
elationship between ischemia and the development of myo-
ardial fibrosis (i.e., LGE); 3) the relationship of clinical
ymptoms, such as chest pain, to ischemia and whether
iomarkers can identify patients with active, ongoing
yocardial ischemia; and 4) more precisely the contribu-
ion of both ischemia and fibrosis to stratification of risk in
CM. Such well-designed studies will also help provide
urther insights into which HCM patients will derive the
reatest benefit from implantation of primary prevention
efibrillators, and limit excessive and unnecessary testing.
There is also a great need to identify pharmacologic
herapies aimed at mitigating ischemia. In this regard, there
s currently interest in drugs such as spironolactone, which
nhibit the renin-angiotensin-aldosterone system and could
mprove coronary microvascular function. Although no
ormal clinical studies have been completed using such
rugs in HCM, evidence derived from patients with hyper-
ensive heart disease (in which there are structural abnor-
alities of the intramural arterioles and resultant replace-
ent fibrosis similar to HCM) (75), and from transgenic
ouse models of HCM, has shown that drugs which inhibit
he renin-angiotensin-aldosterone system can reduce both
oronary microvascular remodeling and fibrosis and improve
iastolic function (76,77). As a result, future clinical inves-
igations directed at assessing the efficacy of such drugs and
heir role in decreasing myocardial ischemia and fibrosis
using PET and CMR) may well prove informative and
linically relevant.linical Implications for
anagement and Conclusions
t is now evident that myocardial ischemia caused by
icrovascular dysfunction occurs in the HCM population
reported largely from tertiary centers) and is an important
athophysiologic component of this complex disease pro-
ess, promoting LV remodeling and impacting on clinical
ourse and outcome (12,15,20,29,35,59–61,72). Recently
here has been substantial progress in identifying the pres-
nce and quantifying the magnitude of myocardial ischemia
nd its sequelae (i.e., myocyte death and replacement
brosis) with contemporary imaging modalities having
road applications in cardiovascular medicine. The patho-
hysiologic cascade of events, beginning with the morpho-
ogic and functional abnormalities of the intramural coro-
ary arterioles promoting blunted MBF during stress, and
eading to myocardial ischemia and eventually replacement
brosis, is a likely therapeutic target for favorably altering
he disease phenotype. Future investigative efforts will focus
n creating diagnostic methods for detecting myocardial
schemia before adverse LV remodeling begins so that
argeted treatment strategies can be developed to mitigate
schemia and alter the natural history of HCM.
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